1Cornier, MA, Despres, JP, Davis, N, et al. (2011) Assessing adiposity: a scientific statement from the American Heart Association. Circulation 124, 1996–2019.
2Hossain, P, Kawar, B & El, NM (2007) Obesity and diabetes in the developing world – a growing challenge. N Engl J Med 356, 213–215.
3Cinti, S, Mitchell, G, Barbatelli, G, et al. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46, 2347–2355.
4Hotamisligil, GS, Shargill, NS & Spiegelman, BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.
5van Erk, MJ, Wopereis, S, Rubingh, C, et al. (2010) Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. BMC Med Genomics 3, 5.
6Gregor, MF & Hotamisligil, GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29, 415–445.
7Pereira, MA, Kottke, TE, Jordan, C, et al. (2009) Preventing and managing cardiometabolic risk: the logic for intervention. Int J Environ Res Public Health 6, 2568–2584.
8Larsen, R, Eilertsen, KE & Elvevoll, EO (2011) Health benefits of marine foods and ingredients. Biotechnol Adv 29, 508–518.
9Melle, W, Ellertsen, B & Skjoldal, HR (2004) Zooplankton: the link to higher trophic levels. In The Norwegian Sea Ecosystem, pp. 148–149 [Skjoldal, HR, editor]. Trondheim: Tapir Academic Press.
10Eilertsen, KE, Maehre, HK, Jensen, IJ, et al. (2012) A wax ester and astaxanthin-rich extract from the marine copepod Calanus finmarchicus attenuates atherogenesis in female apolipoprotein E-deficient mice. J Nutr 142, 508–512.
11Matthews, JN, Altman, DG, Campbell, MJ, et al. (1990) Analysis of serial measurements in medical research. BMJ 300, 230–235.
12Xu, H, Barnes, GT, Yang, Q, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821–1830.
13Hafstad, AD, Khalid, AM, Hagve, M, et al. (2009) Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83, 519–526.
14Kuk, JL, Katzmarzyk, PT, Nichaman, MZ, et al. (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14, 336–341.
15Wang, Y, Rimm, EB, Stampfer, MJ, et al. (2005) Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 81, 555–563.
16Belzung, F, Raclot, T & Groscolas, R (1993) Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am J Physiol 264, R1111–R1118.
17Ruzickova, J, Rossmeisl, M, Prazak, T, et al. (2004) Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 39, 1177–1185.
18Raclot, T, Groscolas, R, Langin, D, et al. (1997) Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res 38, 1963–1972.
19Sato, A, Kawano, H, Notsu, T, et al. (2010) Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 59, 2495–2504.
20Perez-Matute, P, Perez-Echarri, N, Martinez, JA, et al. (2007) Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 97, 389–398.
21Baillie, RA, Takada, R, Nakamura, M, et al. (1999) Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body fat deposition. Prostaglandins Leukot Essent Fatty Acids 60, 351–356.
22Arai, T, Kim, HJ, Chiba, H, et al. (2009) Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice. J Atheroscler Thromb 16, 674–683.
23Gorreta, F, Bernasconi, G, Galliani, G, et al. (2002) Wax esters of n-3 polyunsaturated fatty acids: a new stable formulation as a potential food supplement. 1 – Digestion and absorption in rats. Lebensm Wiss Technol 35, 458–465.
24Whelan, J, Gouffon, J & Zhao, Y (2012) Effects of dietary stearidonic acid on biomarkers of lipid metabolism. J Nutr 142, 630S–634S.
25Voss, AC & Sprecher, H (1988) Metabolism of 6,9,12-octadecatrienoic acid and 6,9,12,15-octadecatetraenoic acid by rat hepatocytes. Biochim Biophys Acta 958, 153–162.
26Parrish, CC, Pathy, DA, Parkes, JG, et al. (1991) Dietary fish oils modify adipocyte structure and function. J Cell Physiol 148, 493–502.
27Lee, MS, Kwun, IS & Kim, Y (2008) Eicosapentaenoic acid increases lipolysis through up-regulation of the lipolytic gene expression and down-regulation of the adipogenic gene expression in 3T3-L1 adipocytes. Genes Nutr 2, 327–330.
28Lorente-Cebrian, S, Bustos, M, Marti, A, et al. (2012) Eicosapentaenoic acid inhibits tumor necrosis factor-α-induced lipolysis in murine cultured adipocytes. J Nutr Biochem 23, 218–227.
29Rustan, AC, Hustvedt, BE & Drevon, CA (1993) Dietary supplementation of very long-chain n-3 fatty acids decreases whole body lipid utilization in the rat. J Lipid Res 34, 1299–1309.
30Berger, JJ & Barnard, RJ (1999) Effect of diet on fat cell size and hormone-sensitive lipase activity. J Appl Physiol 87, 227–232.
31Ren, T, He, J, Jiang, H, et al. (2006) Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J Mol Endocrinol 37, 175–183.
32Ikeuchi, M, Koyama, T, Takahashi, J, et al. (2007) Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem 71, 893–899.
33Looije, NA, Risovic, V, Stewart, DJ, et al. (2005) Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci 8, 400–408.
34Thornton, SJ, Warburton, C, Wasan, KM, et al. (2007) Treatment with a cholesterol absorption inhibitor (FM-VP4) reduces body mass and adipose accumulation in developing and pre-obese mice. Drug Dev Ind Pharm 33, 1058–1069.
35Weisberg, SP, McCann, D, Desai, M, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796–1808.
36Calder, PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 75, 645–662.
37Arunkumar, E, Bhuvaneswari, S & Anuradha, CV (2012) An intervention study in obese mice with astaxanthin, a marine carotenoid – effects on insulin signaling and pro-inflammatory cytokines. Food Funct 3, 120–126.
38Yuan, JP, Peng, J, Yin, K, et al. (2011) Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol Nutr Food Res 55, 150–165.
39Ye, J, Gao, Z, Yin, J, et al. (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293, E1118–E1128.
40Ouchi, N, Parker, JL, Lugus, JJ, et al. (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11, 85–97.
41Bruun, JM, Lihn, AS, Verdich, C, et al. (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285, E527–E533.
42Lamping, K, Nuno, D, Coppey, L, et al. (2013) Modification of high saturated fat diet with n-3 polyunsaturated fat improves glucose intolerance and vascular dysfunction. Diabetes Obes Metab 15, 144–152.
43Preuss, HG, Echard, B, Yamashita, E, et al. (2011) High dose astaxanthin lowers blood pressure and increases insulin sensitivity in rats: are these effects interdependent? Int J Med Sci 8, 126–138.
44Yang, ZH, Miyahara, H, Mori, T, et al. (2011) Beneficial effects of dietary fish-oil-derived monounsaturated fatty acids on metabolic syndrome risk factors and insulin resistance in mice. J Agric Food Chem 59, 7482–7489.
45Gillingham, LG, Harris-Janz, S & Jones, PJ (2011) Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids 46, 209–228.